Robert Weisskoff, Ph.D.
Senior Partner
About
Robert Weisskoff, Senior Partner, joined F-Prime Capital in 2004. Robert has worked extensively in both academia and the bioscience industry for thirty years. Prior to F-Prime, he held various senior roles in R&D and Business Development at both pharmaceutical and medical device companies. In his academic career, Dr. Weisskoff was Associate Professor of Radiology at Harvard Medical School, on the faculty of the Harvard-MIT Health Sciences Technology (HST) Program, and performed research at Massachusetts General Hospital, where he was Associate Director of the MGH-NMR Center. There he worked at the intersection of basic research, medical technology development, and clinical research in a variety of areas. Robert is the author of over 100 peer-reviewed scientific papers, and an inventor on 6 US patents.
Robert holds a Ph.D. in Physics from the Massachusetts Institute of Technology and an M.B.A. from Columbia University. He received his A.B. degree in Physics from Harvard University, graduating magna cum laude and Phi Beta Kappa.
Robert serves on the Board of Directors of Adela, CORE Diagnostics, Plasmagen Biosciences, RareCyte, Shinobi Therapeutics, and Zenflow, Inc. He has previously served on the boards of Accuri Cytometers (acquired by Becton Dickinson), Caribou Biosciences (NASDAQ: CRBU), Farapulse (acquired by Boston Scientific), Ikano Therapeutics (acquired by UCB), Laurus Labs (NSE:LAURUSLABS), Structure Therapeutics (NASDAQ:GPCR), Surface Oncology (NASDAQ:SURF), Tetraphase (NASDAQ:TTPH), Transave (NASDAQ:INSM), Topaz (acquired by Sanofi Pasteur), ViewRay (NASDAQ:VRAY) and Xilio Therapeutics (NASDAQ: XLO).
-
Accuri Cytometers was a life sciences tools company that democratized flow cytometry for medical and pharmaceutical research. Accuri Cytometers was acquired by Becton Dickinson.
-
Category
- MedTech
-
Status
- Acquired
-
Location
Ann Arbor, MI
-
Year Invested
2008
-
Team
-
-
Adela (formerly DNAMx) is focused on the detection of cancer and other high-morbidity, high-mortality conditions through a routine blood test. The company’s genome-wide methylation analysis technology has the unique ability to distinguish the most-highly informative (methylated) regions of the genome from non-informative regions and preferentially target those informative regions for sequencing. Learn more at www.adelabio.com.
-
Category
- MedTech
-
Status
- Private
-
Location
Toronto, Ontario
-
Year Invested
2021
-
Team
-
-
Affinia Therapeutics is a gene therapy company with a platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies and a mission to develop transformative medicines for devastating diseases. Learn more at www.affiniatx.com.
-
Category
- Therapeutics
-
Status
- Private
-
Location
Waltham, MA
-
Year Invested
2019
-
Team
-
-
Amphora Medical was a medical device technology company developing minimally invasive products to restore the quality of life of people suffering from Overactive Bladder Syndrome.
-
Category
- MedTech
-
Status
- Acquired
-
Location
Maple Grove, MN
-
Year Invested
2013
-
Team
-
-
BioConnect Systems was a medical device company that developed a CE-Marked product for improving dialysis access surgery.
-
Category
- MedTech
-
Status
- Private
-
Location
Fort Washington, PA
-
Year Invested
2007
-
Team
-
-
Cadence Neuroscience is a medical device company developing new therapies for the treatment of epilepsy and other neurological disorders. The company’s core technology was developed at Mayo Clinic and is under clinical evaluation. Founded in 2017 and headquartered in Redmond, Washington, Cadence is led by seasoned executives with extensive backgrounds in neural implant product development and clinical studies. Learn more: https://www.cadenceneuro.com/
-
Category
- MedTech
-
Status
- Private
-
Location
Redmond, WA
-
Year Invested
2023
-
Team
-
-
CardioKine is a pharmaceutical company focused on the development of lixivaptan, an oral compound under development for the potential treatment of hyponatremia in patients with congestive heart failure. CardioKine was acquired by Cornerstone Therapeutics.
-
Category
- Therapeutics
-
Status
- Acquired
-
Location
Philadelphia, PA
-
Year Invested
2006
-
Team
-
-
Caribou (NASDAQ:CRBU) is a leading company in CRISPR genome editing founded by pioneers of CRISPR-Cas9 biology. Caribou’s proprietary technologies put the company at the forefront of the development of new medical therapies. Learn more at www.cariboubio.com.
-
Category
- Therapeutics
-
Status
- Public
-
Location
Berkeley, CA
-
Year Invested
2015
-
Team
-
-
Checkmate Pharmaceuticals (NASDAQ: CMPI) is a clinical stage company pursuing a novel approach to specifically activating the innate and adaptive arms of the immune system to recognize and ultimately destroy tumor cells. Checkmate Pharmaceuticals was acquired by Regeneron (NASDAQ:REGH) in 2022.
-
Category
- Therapeutics
-
Status
- Acquired
- Public
-
Location
Cambridge, MA
-
Year Invested
2017
-
Team
-
-
CORE provides high-end diagnostics services for disease stratification and therapy selection. Learn more at www.corediagnostics.in.
-
Category
- MedTech
-
Status
- Private
-
Location
Gurgaon, Haryana, India
-
Year Invested
2016
-
Team
-
-
Cytek Biosciences Inc. (NASDAQ: CTBK) is a leading flow cytometry solution provider that provides compact, affordable instruments with high multiplexing capabilities. Learn more at www.cytekbio.com.
-
Category
- MedTech
-
Status
- Public
-
Location
China
-
Year Invested
2015
-
Team
-
-
Farapulse is a medical device company developing a novel approach to treating a range of arrhythmias using pulsed electric field. Farapulse was acquired by Boston Scientific in 2021.
-
Category
- MedTech
-
Status
- Acquired
-
Location
Menlo Park, CA
-
Year Invested
2016
-
Team
-
-
FoldRx Pharmaceuticals focuses on creating disease modifying drug therapies for diseases of protein misfolding. FoldRx developed, tafamidis, the first-in-class therapy approved or TTR amyloidosis. FoldRx was acquired by Pfizer.
-
Category
- Therapeutics
-
Status
- Acquired
-
Location
Cambridge, MA
-
Year Invested
2004
-
Team
-
-
Ikano Therapeutics is a specialty pharmaceutical company focused on developing Midazolam Nasal Spray (USL261) for acute repetitive seizures. Ikano was acquired by UCB.
-
Category
- Therapeutics
-
Status
- Acquired
-
Location
Montvale, NJ
-
Year Invested
2006
-
Team
-
-
J-Pharma is a clinical stage biopharmaceutical company with a mission to create and develop novel pharmaceuticals. J-Pharma is conducting trials in Japan for advanced stage cancer patients. Learn more at j-pharma.com.
-
Category
- Therapeutics
-
Status
- Private
-
Location
Kanagawa, Japan
-
Year Invested
2020
-
Team
-
-
Laurus Labs (NSE:LAURUSLABS) is a leading manufacturer of Active Pharmaceutical Ingredients (API) for anti-retroviral (HIV-AIDS), oncology, nutraceutical and several other products, with a customer base that spans top-tier generic pharmaceutical companies in India and abroad. Learn more at www.lauruslabs.com.
-
Category
- Therapeutics
-
Status
- Public
-
Location
Hyderabad, India
-
Year Invested
2012
-
Team
-
-
Medwell Ventures Private Unlimited (“Medwell”) is an operator of specialty home healthcare services in India.
-
Category
- Health IT/Services
-
Status
- Private
-
Location
Bangalore, India
-
Year Invested
2015
-
Team
-
-
Metcela is a clinical-stage Kanagawa-based biotech company bringing cell-based therapies to heart failure patients. Learn more at www.metcela.com.
-
Category
- Therapeutics
-
Status
- Private
-
Location
Kanagawa, Japan
-
Year Invested
2018
-
Team
-
-
Plasmagen is an Indian biopharma company that specializing exclusively in Plasma Protein Therapy. Learn more at www.plasmagen.in.
-
Category
- Therapeutics
-
Status
- Private
-
Location
Bangalore, India
-
Year Invested
2017
-
Team
-
-
Promentis Pharmaceuticals, Inc., a privately-held biopharmaceutical company, is developing innovative therapies for neuropsychiatric disorders. Learn more at www.promentispharma.com.
-
Category
- Therapeutics
-
Status
- Private
-
Location
Milwaukee, Wisconsin
-
Year Invested
2016
-
Team
-
-
Quantum Circuits, Inc. (QCI) was founded in 2015 with the goal of developing, manufacturing and selling the first practical and useful quantum computers based on superconducting devices. QCI was founded by pioneers in quantum devices and information processing from the Department of Applied Physics at Yale University. Their group has produced many scientific firsts, including the development of a “quantum bus” for entangling qubits with wires and the first implementation of a quantum algorithms and error-correction with a solid-state device. Learn more: www.quantumcircuits.com
-
Status
- Private
-
Location
New Haven, CT
-
Year Invested
2017
-
Team
-
-
RareCyte offers Precision Biology™ solutions focused on multiplexed analysis of cells and tissue with applications in both research and clinical diagnostics. The Company has deep experience in developing advanced precision life science systems used in cutting-edge labs worldwide. RareCyte customers perform innovative research, bring new therapeutics to market, and perform a wide range of single cell applications in oncology and disease research. Learn more at www.rarecyte.com.
-
Category
- MedTech
-
Status
- Private
-
Location
Seattle, WA
-
Year Invested
2021
-
Team
-
-
Shinobi Therapeutics is a biotechnology company developing a new class of off-the-shelf immune evasive iPSC-derived cell therapies. Based on the research of scientific co-founders Shin Kaneko, M.D., Ph.D., at Kyoto University and Tobias Deuse, M.D., at University of California, San Francisco, Shinobi has created a new allogeneic CD8αβ iPS-T cell platform that demonstrates comprehensive immune evasion from all arms of the immune system. For more information, please visit www.shinobitx.com.
-
Category
- Therapeutics
-
Status
- Private
-
Location
San Francisco, CA and Kyoto, Japan
-
Year Invested
2021
-
Team
-
-
Singular Genomics (NASDAQ: OMIC) is developing a new next generation sequencing platform. Learn more at www.singulargenomics.com.
-
Category
- MedTech
-
Status
- Public
-
Location
La Jolla, CA
-
Year Invested
2019
-
Team
-
-
Structure Therapeutics (NASDAQ: GPCR) is a clinical-stage global biopharmaceutical company discovering and developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Learn more at www.structuretx.com.
-
Category
- Therapeutics
-
Status
- Public
-
Location
Shanghai, China & San Diego, CA
-
Year Invested
2019
-
Team
-
-
Surface Oncology (NASDAQ:SURF) is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment with lead programs targeting CD73, CD39, IL-27 and CD47. Surface Oncology was acquired by Coherus BioSciences.
-
Category
- Therapeutics
-
Status
- Acquired
-
Location
Cambridge, MA
-
Year Invested
2014
-
Team
-
-
Tempest Therapeutics (Nasdaq: TPST) is a development-stage biotechnology company advancing small molecule therapeutics that modulate anti-tumor immunity pathways. Learn more at www.tempesttx.com.
-
Category
- Therapeutics
-
Status
- Public
-
Location
San Francisco, CA
-
Year Invested
2018
-
Team
-
-
Tetraphase (NASDAQ: TTPH) is a biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections; its lead product XERAVATM (eravacycline) is approved for the treatment of complicated intra-abdominal infections by the FDA and EMA. Tetraphase Pharmaceuticals was acquired by La Jolla Pharmaceutical Company.
-
Category
- Therapeutics
-
Status
- Acquired
-
Location
Watertown, MA
-
Year Invested
2006
-
Team
-
-
Topaz Pharmaceuticals is a specialty pharmaceutical company developing a topical prescription product, Sklice, for the treatment of head lice. Topaz Pharmaceuticals was acquired by Sanofi.
-
Category
- Therapeutics
-
Status
- Acquired
-
Location
Horsham, PA
-
Year Invested
2007
-
Team
-
-
Transave is focused on improving the treatment of serious lung diseases through the company’s next generation, proprietary liposomal delivery technology. Transave was acquired by Insmed Inc.
-
Category
- Therapeutics
-
Status
- Acquired
-
Location
Monmouth Junction, NJ
-
Year Invested
2006
-
Team
-
-
Trivitron Healthcare is India’s largest, national wholesale distributor and after-sales support provider of medical equipment and devices. Learn more at www.trivitron.com.
-
Category
- MedTech
-
Status
- Private
-
Location
Chennai, India
-
Year Invested
2012
-
Team
-
-
ViewRay (NASDAQ: VRAY) designs, manufactures and markets the MRIdian® radiation therapy system. Which uses a high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Learn more at viewraysystems.com.
-
Category
- MedTech
-
Status
- Public
-
Location
Oakwood Village, OH
-
Year Invested
2008
-
Team
-
-
Xilio Therapeutics (NASDAQ: XLO) is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. Learn more at www.xiliotx.com.
-
Category
- Therapeutics
-
Status
- Public
-
Location
Waltham, MA
-
Year Invested
2016
-
Team
-
-
Zenflow is a medical device company developing the Spring Implant for patients with benign prostate hyperplasia (BPH). Learn more at www.zenflow.com.
-
Category
- MedTech
-
Status
- Private
-
Location
San Francisco, CA
-
Year Invested
2017
-
Team
-
